Berotralstat
Product Specifications
UNSPSC Description
Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema[1][2].
Target Antigen
Kallikrein
Type
Reference compound
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/berotralstat.html
Purity
99.70
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(C(F)(F)F)=NN1C2=CC(CN)=CC=C2)NC3=CC([C@@H](C4=CC(C#N)=CC=C4)NCC5CC5)=CC=C3F
Molecular Weight
562.56
References & Citations
[1]Zuraw B, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. J Allergy Clin Immunol. 2020;S0091-6749(20)31484-6.|[2]Richard E. Kast, et al. Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma. Neuroglia. 2024, 5(3), 223-233.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-109127/Berotralstat-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-109127/Berotralstat-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
1809010-50-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
